Cholestasis and metabolic bone disease - A clinical review

Wiener Medizinische Wochenschrift

Volumn 158, Issue 19-20, 2008, Pages 553-557

  Gasser, Rudolf W ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Cholestasis; Hepatic osteodystrophy; Metabolic bone disease; Pathophysiology; Treatment

Indexed keywords

ALENDRONIC ACID; BILIRUBIN; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; GLUCOCORTICOID; IBANDRONIC ACID; PAMIDRONIC ACID; PARATHYROID HORMONE; RALOXIFENE; RISEDRONIC ACID; SOMATOMEDIN; VITAMIN D; VITAMIN K GROUP; ZOLEDRONIC ACID;

BILIARY CIRRHOSIS; BONE DENSITY; BONE METABOLISM; CHOLESTASIS; CONFERENCE PAPER; DUAL ENERGY X RAY ABSORPTIOMETRY; FOLLOW UP; FRACTURE; HUMAN; HYPOGONADISM; LIFESTYLE MODIFICATION; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LOW DRUG DOSE; OSTEOLYSIS; OSTEOMALACIA; OSTEOPENIA; OSTEOPOROSIS; PATHOPHYSIOLOGY; RISK FACTOR; VITAMIN METABOLISM;

BONE DENSITY; BONE DISEASES, METABOLIC; CHOLESTASIS, INTRAHEPATIC; CHRONIC DISEASE; FRACTURES, SPONTANEOUS; HUMANS; LIVER CIRRHOSIS; LIVER DISEASES; OSTEOMALACIA; OSTEOSCLEROSIS; RISK FACTORS;

EID: 55949096234     PISSN: 00435341     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10354-008-0594-z     Document Type: Conference Paper

References (40)

1. JE Hay 1995 Bone disease in cholestatic liver disease Gastroenterology 108 276 283
2. S Rouillard NE Lane 2001 Hepatic osteodystrophy Hepatology 33 301 307
3. T Pusl U Beuers 2005 Extrahepatic manifestations of cholestatic liver diseases pathogenesis and therapy Clin Rev Allerg Immunol 28 147 157
4. J Hay M Guichelaar K Egan T Therneau 2000 Bone mineral density in the first decade after liver transplantation Hepatology 32 239A abstract
5. MMJ Guichelaar M Malinchoc J Sibonga BL Clarke JE Hay 2002 Bone metabolism in advanced cholestatic liver disease: analysis by bone histomorphometry Hepatology 36 895 903
6. Z Ackerman M Weinreb G Amir RD Pollak 2002 Bone mineral metabolism and histomorphometry in rats with cholestatic liver disease Liver 22 166 172
7. M Weinreb RD Pollak Z Ackerman 2004 Experimental cholestatic liver disease through bile-duct ligation in rats results in skeletal fragility and impaired osteoblastogenesis J Hepatol 40 385 390
8. A Pares N Guanabens J Rodes 2005 Gene polymorphisms as predictors of decreased bone mineral density and osteoporosis in primary biliary cirrhosis Eur J Gastroenterol Hepatol 17 311 315
9. JE Hay 2003 Osteoporosis in liver diseases and after liver transplantation J Hepatol 38 856 865
10. DS Matloff MM Kaplan RM Neer MJ Goldberg W Bitman HJ Wolfe 1982 Osteoporosis in primary biliary cirrhosis: effects of 25-hydroxyvitamin D3 treatment Gastroenterology 83 97 102
11. HF Herlong RR Recker WC Maddrey 1982 Bone disease in primary biliary cirrhosis: histologic features and response to 25-hydroxyvitamin D Gastroenterology 83 103 108
12. KV Kowdley MJ Emond JA Sadoeski MM Kaplan 1997 Plasma vitamin K1 level is decreased in primary biliary cirrhosis Am J Gastroenterol 92 2059 2061
13. S Nishiguchi S Shimoi H Kurooka A Tamori D Habu T Takeda S Kubo 2001 Randomized pilot trial of vitamin K2 for bone loss in patients with primary biliary cirrhosis J Hepatol 35 543 545
14. AT de Albuquerque Taveira MIM Fernandes LC Galvao R Sawamura E de Mello Vieira FJ Albuquerque de Paula 2007 Impairment of bone mass development in children with chronic cholestatic liver disease Clinical Endocrinology 66 518 523
15. CH Janes ER Dickson R Okazaki S Bonde AF McDonagh BL Riggs 1995 Role of Hyperbilirubinemia in the impairment of osteoblast proliferation associated with cholestatic jaundice J Clin Invest 95 2581 2586
16. K Menon P Angulo S Weston E Dickson K Lindor 2001 Bone disease in primary biliary cirrhosis: independent indicators and rate of progression J Hepatol 35 316 323
17. DL Smith NJ Shire NB Watts T Schmitter G Szabo SD Zucker 2006 Hyperbilirubinemia is not a major contributing factor to altered bone mineral density in patients with chronic liver disease J Clin Densitom 9 105 113
18. F Szalay D Hegedus PL Lakatos I Tornai E Bajnok K Dunkel P Lakatos 2003 High serum osteoprotegerin and low RANKL in primary biliary cirrhosis J Hepatol 38 395 400
19. A Monegal M Navasa P Peris L Alvarez F Pons J Rodes N Guanabens 2007 Serum osteoprotegerin and its ligand in cirrhotic patients referred for orthotopic liver transplantation: relationship with metabolic bone disease Liver Int 27 492 497
20. AR Moschen A Kaser S Stadlmann G Millonig S Kaser P Mühllechner A Habior I Graziadei W Vogel H Tilg 2005 The RANKL/OPG system and bone mineral density in patients with chronic liver disease J Hepatol 43 973 983
21. H Bell N Raknerud JA Falch E Haug 1995 Inappropriately low levels of gonadotrophins in amenorrhoeic women with alcoholic and non-alcoholic cirrhosis Eur J Endocrinol 132 444 449
22. S Pignata B Daniele MG Galati G Esposito P Vallone F Fiore P Ricchi M Pergola 1997 Oestradiol and testosterone blood levels in patients with viral cirrhosis and hepatocellular carcinoma Eur J Gastroenterol Hepatol 9 283 286
23. E Garcia-Valdecasas-Campelo E Gonzalez-Reimers F Santolaria-Fernandez MJ De la Vega-Prieto A Milena-Abril MJ Sanchez-Perez A Martinez-Riera MDLA Gomez-Rodriguez 2006 Serum osteoprotegerin and RANKL levels in chronic alcoholic liver disease Alcohol Alcoholism 41 261 266
24. M Prince E Christensen C Gluud 2005 Glucocorticosteroids for primary biliary cirrhosis Cochrane Database Syst Rev Apr 18 2 CD003778
25. Chen W, Gluud C. Glucocorticosteroids for primary sclerosing cholangitis. Cochrane Database Syst Rev, (3): CD004036, 2004
26. JE Hay MMJ Guichelaar 2005 Evaluation and management of osteoporosis in liver disease Clin Liver Dis 9 747 766
27. Report of WHO Study Group 1994 Assessment of fracture risk and its application to screening for postmenopausal osteoporosis World Health Organ Tech Rep Ser 843 1 129
28. JD Collier M Ninkovic JE Compston 2002 Guidelines on the management of osteoporosis associated with chronic liver disease Gut 50 Suppl I i1 i9
29. A Pares N Guanabens 2006 Treatment of bone disorders in liver disease J Hepatol 45 445 453
30. NM Maalouf K Sakhaee 2006 Treatment of osteoporosis in patients with chronic liver disease and in liver transplant recipients Curr Treatment Options Gastroenterol 9 456 463
31. N Guanabens A Pares I Ros L Alvarez F Pons L Caballeria A Monegal MJ Martinez de Osaba M Roca P Peris J Rodes 2003 Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis Am J Gastroenterol 98 2268 2274
32. CO Zein RA Jorgensen B Clarke DE Wenger JC Keach P Angulo KD Lindor 2005 Alendronate improves bone mineral density in primary biliary cirrhosis: a randomised placebo-controlled trial Hepatology 42 762 771
33. C Levy DM Harnois P Angulo R Jorgensen KD Lindor 2005 Raloxifene improves bone mass in osteopenic woman with primary biliary cirrhosis: results of a pilot study Liver Int 25 117 121
34. SP Pereira J O'Donohue C Moniz MG Phillips H Abraha M Buxton-Thomas R Williams 2004 Transdermal hormonal replacement therapy improves vertebral bone density in primary biliary cirrhosis: results of a 1-year controlled trial Aliment Pharmacol Ther 19 563 570
35. S Ormarsdottir H Mallmin T Naessen M Petren-Mallmin U Broome R Hultcranz L Lööf 2004 An open, randomized, controlled study of transdermal hormone replacement therapy on the rate of bone loss in primary biliary cirrhosis J Intern Med 256 63 69
36. RH Boone AM Cheung LM Girlan EJ Heathcote 2006 Osteoporosis in primary biliary cirrhosis: a randomized trial of the efficacy and feasibility of estrogen/progestin Dig Dis Sci 51 1103 1112
37. JE Rossouw GL Anderson RL Prentice AZ LaCroix C Kooperberg ML Stefanick RD Jackson SA Beresford BV Howard KC Johnson JM Kotchen J Ockene Writing group for the Women's Health Initiative Investigators 2002 Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial JAMA 288 321 333
38. MMJ Guichelaar R Kendall M Malinchoc JE Hay 2006 Bone mineral density before and after OLT: long-term follow-up and predictive factors Liver Transpl 12 1390 1402
39. G Millonig IW Graziadei D Eichler KP Pfeiffer G Finkenstedt P Muehllechner A Koenigsrainer R Margreiter W Vogel 2005 Alendronate in combination with calcium and vitamin D prevents bone loss after orthotopic liver transplantation: a prospective single-center study Liver Tanspl 11 960 966
40. BAL Crawford C Kam J Pavlovic K Byth DJ Handelsman PW Angus GW McCaughan 2006 Zoledronic acid prevents bone loss after liver transplantation: a randomized, double-blind, placebo-controlled trial Ann Intern Med 144 239 248